Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most of the listed AI claims relate to lower blood pressure, kidney function, hyperkalemia, angioedema, monitoring, and drug interactions, but the provided FDA label excerpts only address fetal toxicity/pregnancy. Because the majority of safety/monitoring/interaction statements cannot be verified against the supplied label text, alignment is only partial.
Category Scores
Accurate Statements
ENTRESTO can cause fetal harm when administered to a pregnant woman; renin-angiotensin system drugs can reduce fetal renal function and increase fetal/neonatal morbidity and death; when pregnancy is detected, consider alternative treatment and discontinue ENTRESTO; closely observe neonates for hypotension, oliguria, and hyperkalemia after in utero exposure.
Supported by provided excerpts from 5.1 and 8.1 (Fetal Toxicity and Pregnancy sections).
Unsupported Statements
Entresto can commonly cause symptoms related to lower blood pressure, such as dizziness and feeling lightheaded.
No label excerpts provided for hypotension/dizziness frequency or commonality.
Entresto can cause worsening kidney function in some people.
No provided label excerpt discussing postnatal kidney function worsening.
Entresto-related worsening kidney function risk is especially higher in people who already have kidney disease or low blood pressure risk factors.
No provided label excerpt supporting risk stratification by kidney disease or low blood pressure risk factors.
Entresto can cause angioedema (swelling of the face, lips, tongue, or throat).
No provided label excerpt on angioedema.
Entresto can cause severe hypotension (fainting and dizziness that does not improve) if blood pressure drops too far.
No provided label excerpt supporting severity descriptions or fainting/does not improve language.
Entresto can contribute to high potassium in certain patients.
No provided label excerpt for hyperkalemia in general patients.
Entresto can contribute to kidney function changes in certain patients.
No provided label excerpt supporting kidney function changes outside pregnancy/neonatal context.
In some patients, warning signs of high potassium or kidney function changes may include weakness, abnormal heart rhythms, or reduced urine output.
No provided label excerpt linking these specific clinical signs to hyperkalemia/renal changes.
Entresto is not an ACE inhibitor.
No provided label excerpt addressing class relationship to ACE inhibitors.
The risk of cough is generally lower with Entresto than with ACE inhibitors.
No provided label excerpt comparing cough risk versus ACE inhibitors.
Cough can still occur in some patients taking Entresto.
No provided label excerpt discussing cough incidence with Entresto.
People with chronic kidney disease are more likely to have kidney function and potassium-related side effects from Entresto.
No provided label excerpt supporting CKD as a risk factor.
People who already have elevated potassium are more likely to have kidney function and potassium-related side effects from Entresto.
No provided label excerpt supporting baseline hyperkalemia as a risk factor.
Older adults are more likely to have kidney function and potassium-related side effects from Entresto.
No provided label excerpt supporting age-related risk.
Taking other medicines that raise potassium (such as certain potassium-sparing diuretics or potassium supplements) increases the likelihood of kidney function and potassium-related side effects from Entresto.
No provided label excerpt on drug-drug interactions involving potassium-elevating therapies.
Monitoring is important after starting or changing the dose of Entresto.
No provided label excerpt on monitoring recommendations.
Entresto can interact with other blood pressure–lowering therapies and kidney-impacting therapies, increasing the chance of dizziness, low blood pressure, kidney function changes, or high potassium.
No provided label excerpt on interactions.
Patients should avoid taking Entresto with other medicines that increase angioedema risk.
No provided label excerpt on angioedema risk with concomitant drugs.
Clinicians commonly check blood pressure after starting Entresto and after dose adjustments.
No provided label excerpt on blood pressure monitoring.
Clinicians commonly check kidney function and potassium levels after starting Entresto and after dose adjustments.
No provided label excerpt on kidney function/potassium monitoring.
Lab monitoring often includes kidney function and potassium levels because these can change early in treatment with Entresto.
No provided label excerpt supporting timing/frequency of lab changes.
Patients should contact their prescriber promptly for persistent dizziness or lightheadedness while taking Entresto.
No provided label excerpt for patient instructions about dizziness/lightheadedness.
Patients should contact their prescriber promptly for symptoms suggesting allergic swelling (face or lip or tongue swelling) while taking Entresto.
No provided label excerpt with patient instructions for angioedema symptoms.
Patients should contact their prescriber promptly for fainting while taking Entresto.
No provided label excerpt for patient instructions about fainting.
Patients should contact their prescriber promptly for signs of significant weakness or reduced urine output while taking Entresto.
No provided label excerpt for patient instructions about weakness/reduced urine output (other than the pregnancy/neonatal monitoring in 8.1).
Swelling involving the tongue or throat or breathing affected while taking Entresto is an emergency.
No provided label excerpt using emergency framing or breathing-affected wording.
DrugPatentWatch.com tracks drug patent or exclusivity and related filings and has a page where Entresto status can be reviewed.
Not supported by the provided FDA label excerpts (and the statement concerns a third-party website rather than prescribing information).
Contradictions
Important Omissions
The AI claims about hypotension, angioedema, hyperkalemia, kidney function changes, monitoring, and drug interactions cannot be checked for completeness/accuracy because the provided FDA excerpts do not include the label sections that would typically contain these details (e.g., Warnings/Precautions, Adverse Reactions, Drug Interactions, and Dosage/Administration or Monitoring guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Many safety-related claims (hypotension symptoms, angioedema, hyperkalemia, kidney effects, monitoring, interaction avoidance) are not verifiable against the supplied label excerpts. Unverified or potentially imprecise patient guidance could affect safe use, even though no direct contradictions with the provided excerpts were identified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Insufficient FDA label coverage in the provided excerpts to verify most AI safety/monitoring/interaction claims; only fetal toxicity/pregnancy statements can be confirmed.
Suggested Improvement
Evaluate and revise claims using the specific FDA label sections for Warnings/Precautions, Adverse Reactions, Drug Interactions, and Patient Instructions/Monitoring; ensure each claim is directly supported by the provided label text.